Drug Profile
Research programme: HDL modulators - AbbVie
Alternative Names: HDL modulators research programme - Abbott; KH01500; KH01501; KH01502Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kos Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lipid metabolism disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lipid-metabolism-disorders in USA (PO)
- 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
- 23 Aug 2005 Preclinical trials in Lipid metabolism disorders in USA (PO)